News for ImmunityBio, Inc. (IBRX)

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.

ImmunityBio Inc (IBRX), a prominent immunotherapy company, has released its financial results for the fourth quarter and full year ending December 31, 2024. The

Texas-based Interactive Strength Inc. (TRNR) is up over 30 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

U.S. stocks were lower, with the Dow Jones falling over 200 points on Wednesday. Shares of Garmin Ltd. GRMN rose sharply during Wednesday's session after the c...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source of BCG." Specifically, the company will now be able to provide this alternative...

U.S. stock futures were lower this morning, with the Dow futures falling around 500 points on Monday. Shares of Tesla, Inc. TSLA fell sharply in today's pre-ma...

A lot is happening in the market, especially within the growth sectors.

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Brinker International, Inc. EAT gained 12.8% to $174.33 after the ...

ImmunityBio partners with BeiGene for Phase 3 trial combining tislelizumab and ANKTIVA to improve survival in non-small cell lung cancer patients.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a look at where ImmunityBio, Inc.

We recently compiled a list of the These 10 Firms Dominated Last Week's Rally. In this article, we are going to take a look at where ImmunityBio, Inc.

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where Immunitybio, Inc.

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click for our IBRX stock update.

We recently compiled a list of the 10 Firms Shine Amid Wall Street's Lackluster Trading. In this article, we are going to take a look at where ImmunityBio, Inc.

ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United States, European Union and United Kingdom. Read more here.

U.S. stocks were lower, with the Dow Jones index falling almost 100 points on Thursday. Shares of Symbotic Inc. SYM rose sharply during Thursday's session afte...

ImmunityBio Inc (IBRX), a prominent immunotherapy company, has announced significant advancements in its discussions with the U.S. Food and Drug Administration

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. F